Therefore, on top of PI3K inhibition, adding a BET inhibitor that further attenuates RAS activation and also upregulates IQGAP3 could result in the death of lymphoma cells that mainly thrive on the activation of these pathways. Here, IQGAP3 is linked to lymphoma.